Seven-Day Vein-to-Vein Point-of-Care–Manufactured CD19 CAR T-Cell Therapy (GLPG5201) in R/R CLL Including Richter Transformation: Results from the Phase 1 Euplagia-1 Trial
Natalia Tovar
February 16, 2024
Presentations
Impact of CART Cells on the Role of HCT in Lymphoma - Anna Sureda
To Bridge or not to Bridge before CAR T-cell therapy - Anna Dodero
Featured presentations
Document
Document
Document